CoChat
Sign Up
Cited by 63Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.

Linking Metabolic Reprogramming, Plasticity and Tumor Progression

Open access
Shuvalov, Oleg, Daks, Alexandra, Fedorova, Olga, Petukhov, Alexey, Barlev, Nickolai·2021·Cancers
DOI 10.3390/cancers13040762PMC PMC7917602
Open this paper in CoChat — free accountOpen PDF

Abstract

The specific molecular features of cancer cells that distinguish them from the normal ones are denoted as “hallmarks of cancer”. One of the critical hallmarks of cancer is an altered metabolism which provides tumor cells with energy and structural resources necessary for rapid proliferation. The key feature of a cancer-reprogrammed metabolism is its plasticity, allowing cancer cells to better adapt to various conditions and to oppose different therapies. Furthermore, the alterations of metabolic pathways in malignant cells are heterogeneous and are defined by several factors including the tissue of origin, driving mutations, and microenvironment. In the present review, we discuss the key features of metabolic reprogramming and plasticity associated with different stages of tumor, from primary tumors to metastases. We also provide evidence of the successful usage of metabolic drugs in anticancer therapy. Finally, we highlight new promising targets for the development of new metabolic drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13040762

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Different stages of tumor are associated with specific metabolic features. During the cancer development, neoplastic cells pass through several stages: tumor initiation, growth, intravasation into blood or lymph vessels, and dissemination across the body, extravasation, and Mesenchymal–Epithelial Transition (MET) to colonize appropriate niches. These events are associated with various challenges and require metabolic plasticity. GSH—glutathione; NADPH—Nicotinamide adenine dinucleotide phosphate; Arrows mean increasing the amount of GSH or NADPH; E/M—“hybrid” epithelial/mesenchymal state. Explanations are given in the text.
Figure 1 Different stages of tumor are associated with specific metabolic features. During the cancer development, neoplastic cells pass through several stages: tumor initiation, growth, intravasation into blood or lymph vessels, and dissemination across the body, extravasation, and Mesenchymal–Epithelial Transition (MET) to colonize appropriate niches. These events are associated with various challenges and require metabolic plasticity. GSH—glutathione; NADPH—Nicotinamide adenine dinucleotide phosphate; Arrows mean increasing the amount of GSH or NADPH; E/M—“hybrid” epithelial/mesenchymal state. Explanations are given in the text.CC BY · PubMed Central
Figure 2 Several examples of the oncogene-mediated regulation of metabolic reprogramming. AKT upregulates oncogenic c-Myc and HIF1 and concomitantly downregulates the tumor suppressor FoxO. In turn, transcription factors HIF1, c-Myc, and FoxO (marked by specific geometric figures) regulate expression levels of enzymes indicated. ENO—enolase; PFK—phosphofructokinase; PK—pyruvate kinase; ASCT2—Solute Carrier Family 1 Member 5; PSAT—phosphoserine aminotransferase; PSPH—phosphoserine phosphatase; SHMT2—Serine Hydroxymethyltransferase 2; CAD—Carbamoyl-Phosphate Synthetase 2; Aspartate Transcarbamylase, And Dihydroorotase.
Figure 2 Several examples of the oncogene-mediated regulation of metabolic reprogramming. AKT upregulates oncogenic c-Myc and HIF1 and concomitantly downregulates the tumor suppressor FoxO. In turn, transcription factors HIF1, c-Myc, and FoxO (marked by specific geometric figures) regulate expression levels of enzymes indicated. ENO—enolase; PFK—phosphofructokinase; PK—pyruvate kinase; ASCT2—Solute Carrier Family 1 Member 5; PSAT—phosphoserine aminotransferase; PSPH—phosphoserine phosphatase; SHMT2—Serine Hydroxymethyltransferase 2; CAD—Carbamoyl-Phosphate Synthetase 2; Aspartate Transcarbamylase, And Dihydroorotase.CC BY · PubMed Central
Figure 3 Epithelial-to-mesenchymal transition (EMT), its molecular drivers, and metabolic features. The process of EMT is triggered by various autocrine and paracrine factors, including TGF-β, PI3K, and AKT. In addition, certain metabolic factors (alterations of glucose level, deregulation of lipid metabolism, loss of function mutations in several TCA genes can also trigger EMT. The metabolic changes alter homeostasis of epigenetics through the accumulation of particular metabolites. EMT master-regulators (Zeb, Snail, and Twist families) as well as other inducers and coregulators of EMT (TGF-β, AKT, K-RASmut, HIF1α, c-Myc) are able to directly regulate glycolysis and lipid metabolism. All arrows mean “increase”, whereas “bars” mean inhibition. Red color—names of proteins, black color—processes and description. More explanations are given in the text.
Figure 3 Epithelial-to-mesenchymal transition (EMT), its molecular drivers, and metabolic features. The process of EMT is triggered by various autocrine and paracrine factors, including TGF-β, PI3K, and AKT. In addition, certain metabolic factors (alterations of glucose level, deregulation of lipid metabolism, loss of function mutations in several TCA genes can also trigger EMT. The metabolic changes alter homeostasis of epigenetics through the accumulation of particular metabolites. EMT master-regulators (Zeb, Snail, and Twist families) as well as other inducers and coregulators of EMT (TGF-β, AKT, K-RASmut, HIF1α, c-Myc) are able to directly regulate glycolysis and lipid metabolism. All arrows mean “increase”, whereas “bars” mean inhibition. Red color—names of proteins, black color—processes and description. More explanations are given in the text.CC BY · PubMed Central
Figure 4 The scheme of metabolic pathways which are targeted in clinical oncology. The scheme shows metabolic pathways and the key enzymes (shown in red) involved in these processes. Inhibitors that are used as anticancer therapeutics (shown in pink) are also shown. Malignant cells consume energy mainly through utilizing glucose, fatty acids, and glutamine. The process of glycolysis begins with glycose phosphorylation and culminates with pyruvate, which then enters the TCA cycle in mitochondria. Pyruvate is also converted to lactate to maintain high levels of glycolysis. Lactate is exported from the cells mainly by Monocarboxylate carrier 1 (MCT-1) (which is inhibited by AZD3965 and lonidamide) to prevent intracellular acidosis. Fatty acids are transported inside mitochondria by Carnitine Palmitoyltransferase (CPT-1) (which is inhibited by Etomoxir). This step limits their beta-oxidation. The latter is the source of energy consumed by cancer cells via acetyl-CoA entering the TCA cycle. Additionally, cancer cells, unlike nonmalignant ones, are able to synthesize fatty acids. Fatty acid synthase (FASN) (which is inhibited by TVB-2640) mediates the limiting repeating step in this process. Mutated enzymes of the TCA cycle, isocitrate dehydrogenase 1 (IDH1) and IDH2, can be targeted by ivosedinib and edasidenib, respectively. Glutamine is converted to glutamate by Glutaminase (GLS) enzyme (which is inhibited by CB-839) and then to alpha-ketoglutarate in the next step reaction. Alpha-ketoglutarate, in turn, enters the TCA cycle and may be used for either energy production or anabolic metabolism (anaplerosis). The pivotal part of the one-carbon metabolism is the folate cycle, which can be inhibited by methotrexate and pemetrexed via inhibition of DHFR. The one-carbon metabolism provides one-carbon donor groups for biosynthesis of different compounds including nucleotides that are the rate-limiting factor for DNA synthesis and hence, proliferation of cancer cells. Fluouracil (5-FU), raltitrexed, and pemetrexed all inhibit Thymidylate Synthase (TS), whereas gemcitabine inhibits Ribonucleotide reductase (RNR). Detailed explanations are given in the text.
Figure 4 The scheme of metabolic pathways which are targeted in clinical oncology. The scheme shows metabolic pathways and the key enzymes (shown in red) involved in these processes. Inhibitors that are used as anticancer therapeutics (shown in pink) are also shown. Malignant cells consume energy mainly through utilizing glucose, fatty acids, and glutamine. The process of glycolysis begins with glycose phosphorylation and culminates with pyruvate, which then enters the TCA cycle in mitochondria. Pyruvate is also converted to lactate to maintain high levels of glycolysis. Lactate is exported from the cells mainly by Monocarboxylate carrier 1 (MCT-1) (which is inhibited by AZD3965 and lonidamide) to prevent intracellular acidosis. Fatty acids are transported inside mitochondria by Carnitine Palmitoyltransferase (CPT-1) (which is inhibited by Etomoxir). This step limits their beta-oxidation. The latter is the source of energy consumed by cancer cells via acetyl-CoA entering the TCA cycle. Additionally, cancer cells, unlike nonmalignant ones, are able to synthesize fatty acids. Fatty acid synthase (FASN) (which is inhibited by TVB-2640) mediates the limiting repeating step in this process. Mutated enzymes of the TCA cycle, isocitrate dehydrogenase 1 (IDH1) and IDH2, can be targeted by ivosedinib and edasidenib, respectively. Glutamine is converted to glutamate by Glutaminase (GLS) enzyme (which is inhibited by CB-839) and then to alpha-ketoglutarate in the next step reaction. Alpha-ketoglutarate, in turn, enters the TCA cycle and may be used for either energy production or anabolic metabolism (anaplerosis). The pivotal part of the one-carbon metabolism is the folate cycle, which can be inhibited by methotrexate and pemetrexed via inhibition of DHFR. The one-carbon metabolism provides one-carbon donor groups for biosynthesis of different compounds including nucleotides that are the rate-limiting factor for DNA synthesis and hence, proliferation of cancer cells. Fluouracil (5-FU), raltitrexed, and pemetrexed all inhibit Thymidylate Synthase (TS), whereas gemcitabine inhibits Ribonucleotide reductase (RNR). Detailed explanations are given in the text.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 205 references

Cited by

Sorted by citations

See all 63

Related

Metadata

Authors
Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N.
Affiliations
  • Institute of Cytology (RU)
  • Federal Almazov North-West Medical Research Centre (RU)
  • Moscow Institute of Physics and Technology (RU)
Corresponding author
Barlev, Nickolai
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2021-02-12
Volume
13
Issue
4
Pages
762
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers13040762
PMC
PMC7917602
OpenAlex
W3132705638
Cited by
63
References
205
Citations by year
2026: 13 · 2025: 13 · 2024: 10 · 2023: 6 · 2022: 14 · 2021: 7
FWCI
1.12
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Russian Science Foundation (#19-45-02011)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
tumor metabolic reprogramming, metabolic plasticity, tumor progression, cancer hallmarks, tumor microenvironment, metastasis, metabolic drugs, cancer therapy, tumor heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review